Clinical Trial Update: An Investigation of Psilocybin on Behavioural and Cognitive Symptoms of Adults With Fragile X Syndrome [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating psilocybin for behavioral and cognitive symptoms in adults with Fragile X syndrome has been suspended.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fragile Syndrome

Drugs mentioned

• Psilocybin (psilocybin)

Snippet

Sponsor: Nova Mentis Life Science Corp | Conditions: Fragile X Syndrome, Behavior | Phase 2 | Status: SUSPENDED